NCT03807102 (TVATLC01) is a Phase 1, PHASE2 clinical trial of Tumor Vaccine in Lung Cancer, sponsored by Yongchang Zhang.

Who is sponsoring NCT03807102?

NCT03807102 is sponsored by Yongchang Zhang.

What drugs are being tested in NCT03807102?

Interventions in NCT03807102: Tumor Vaccine.

What condition does NCT03807102 study?

NCT03807102 studies Lung Cancer.

Is NCT03807102 still recruiting?

NCT03807102 is currently status unknown. Last updated 29 December 2023.

Last reviewed 2023-12-29 · How we verify

NCT03807102: TVATLC01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer

Status unknown Phase 1, PHASE2 Last updated 29 December 2023

What this trial tests

Phase 1, PHASE2 trial testing Tumor Vaccine in Lung Cancer in 30 participants. Status unknown.

Timeline

16 January 2024

Primary endpoint
31 January 2025

31 January 2026

Quick facts

Lead sponsor	Yongchang Zhang
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	16 January 2024
Primary completion	31 January 2025
Estimated completion	31 January 2026
Sites	1 location across China

Drugs / interventions tested

Tumor Vaccine — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Yongchang Zhang — full company profile →

Who can join

Adults 18 to 70, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tumor vaccines may make the body build an immune response to kill tumor cells. This research study is evaluating a new type of tumor vaccine termed as "Neoantigen Tumor Vaccine". The purpose of this phase I/II trial study is to assess the safety and effectiveness of neoantigentumor vaccine in post radical operation patients with stage IIIA lung cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
Sobhani N, Scaggiante B, Morris R, Chai D, et al · · 2022 · cited 57× · PMID 35759856 · DOI 10.1016/j.ctrv.2022.102429
Neoantigen cancer vaccines: a new star on the horizon.
Li X, You J, Hong L, Liu W, et al · · 2023 · cited 31× · PMID 38164734 · DOI 10.20892/j.issn.2095-3941.2023.0395
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
Chiu LC, Lin SM, Lo YL, Kuo SC, et al · · 2021 · cited 15× · PMID 34201650 · DOI 10.3390/vaccines9070689
Cancer vaccines: an update on recent achievements and prospects for cancer therapy.
Chekaoui A, Garofalo M, Gad B, Staniszewska M, et al · · 2024 · cited 8× · PMID 39720956 · DOI 10.1007/s10238-024-01541-7
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects.
Li X, Zhu YJ, Xue Y, Chen TT, et al · · 2025 · cited 6× · PMID 40563603 · DOI 10.3390/cancers17121953
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.
Xie N, Shen G, Huang C, Zhu H. · · 2025 · cited 2× · PMID 40757404 · DOI 10.1097/cm9.0000000000003708
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy.
Peng Y, Zhan L, Shi J, Wang J, et al · · 2025 · PMID 41079643 · DOI 10.1002/mco2.70321

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Yongchang Zhang trials

Trials by the same sponsor.

NCT04777175 — A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer · recruiting
NCT05530785 — Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT · NA · unknown
NCT04144608 — Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC · Phase 2 · completed
NCT06521034 — First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer · Phase 1, PHASE2 · completed
NCT04144569 — PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03807102 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yongchang Zhang
Last refreshed: 29 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03807102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing